Catalyze Digital Biomarker Innovation Through Collaboration

 Kate Lyden  January 27, 2022  0 Comments

Industry and academia each play important roles in advancing wearable technologies and digital biomarkers to develop life-changing drugs and therapies. Still, successful relationships between the two groups are not nearly as prevalent as they could – or should – be. In this presentation, Kate Lyden, VivoSense Chief Science Officer, discusses the motivation for academia and industry to work together, where the overlap lies, and opportunities for moving forward together.

Here are a few key takeaways from the presentation about how academia and industry can collaborate to improve patient outcomes.

  • Industry-sponsored investigations: Thoughtful and structured relationships that go beyond sharing code and algorithms.
  • Consultancy engagements. Industry seeking the expertise of academics and academics identifying the use cases industry should support.
  • Joint appointments. Opportunities for adjunct science faculty positions in the industry.
  • Cost-sharing or no-cost pledges of support: Industry partners’ letters of support or matched funding to help academic researchers get the funding they need.
  • Hire post-docs and academics: Build bridges between industry and academic research laboratories.

At the end of the rainbow, the pot of gold is a developed Industry-Academia Consortium. Industry gets experts in developing real-world digital clinical measures, and academics get the opportunity to work on relevant challenges and problems. It’s a win-win that will catalyze wearables and digital biomarker innovation.

4 Key Principles of Digital Biomarker Development eBook Read it Today!


Subscribe to Email Updates

Stay Connected